
The article analyzes specific options strategies for AstraZeneca (AZN) stock, currently trading at $70.00. Selling the $66.00 put offers a potential 10.29% annualized return (YieldBoost) with a 77% chance of expiring worthless, allowing for discounted share acquisition if assigned. Alternatively, selling the $72.00 covered call provides a potential 20.74% annualized return (YieldBoost) with a 58% chance of expiring worthless, enhancing income on existing AZN holdings. These strategies illustrate how options can be leveraged for income generation or strategic entry points, with implied volatilities of 33% and 26% respectively, against a trailing 12-month volatility of 24%.
The current options market for AstraZeneca (AZN), trading at $70.00, presents distinct opportunities for income generation and strategic positioning. For investors seeking to acquire the stock at a discount, selling the $66.00 put contract offers an 80-cent premium, establishing an effective cost basis of $65.20 if assigned—a 6% discount to the current market price. Analytical models suggest a 77% probability of this out-of-the-money put expiring worthless, which would yield a 10.29% annualized return on the required capital. Alternatively, for current shareholders, a covered call strategy at the $72.00 strike yields a $1.71 premium. This offers a potential total return of 5.30% if the stock is called away, or a 20.74% annualized yield boost if the option expires worthless, an outcome with a 58% probability. Notably, the implied volatilities for the put (33%) and call (26%) are elevated compared to the stock's 24% trailing twelve-month historical volatility, indicating that option premiums may be rich relative to recent price behavior, enhancing the appeal of these yield-focused strategies.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment